

BC Cancer ST Program Updates for April 2026

AFFECTED APPLICATION(S)	PowerChart
AFFECTED AREA(S)	BC Cancer Sites / VCH Oncology Sites
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the BC Cancer Systemic Therapy (ST) Program will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient’s care.

For Providers:

- For PowerPlans that are versioned: If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop-up window will appear to indicate a new version is required.
 - Click Yes to accept the new version.
 - Do not use the Copy Forward functionality to ensure that the updates apply.



- **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of premed, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).

Please see this month's changes below.

Protocols: LYDARCBDF

Cycles/PowerPlans: Associated treatment PowerPlans

Changes:

- Pre-selected **Troponin I Cardiac High Sensitivity order** moved down to **If clinically indicated** and unselected the order

ONCP LY LYDARCBDF Cycle 1 - Cycle 1, Labs (Day 8, 15, 22, 29) (Future Pending) *Est. 17-Mar-2026 08:00 PDT - 28 Days					
Component	Day 8	Day 15	Day 22	Day 29	
Component	Future Pending *Est. 17-Mar-202...	Future Pending *Est. 24-Mar-202...	Future Pending *Est. 31-Mar-202...	Future Pending *Est. 07-Apr-202...	
	Actions ▾	Actions ▾	Actions ▾	Actions ▾	
<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit				Planned	
<input checked="" type="checkbox"/> Creatinine and Estimated GFR Blood, once, Order for future visit				Planned	
<input checked="" type="checkbox"/> Albumin Creatinine Ratio Urine Random Urine, once, Order for future visit				Planned	
<input checked="" type="checkbox"/> If clinically indicated:					
<input type="checkbox"/> CBC and Differential Blood, once, Order for future visit					
<input type="checkbox"/> Creatinine and Estimated GFR Blood, once, Order for future visit					
<input type="checkbox"/> Albumin Level Blood, once, Order for future visit					
<input type="checkbox"/> Protein Electrophoresis Urine Urine, once, Order for future visit					
<input type="checkbox"/> Immunoglobulin Panel (IgA, IgG, IgM) Blood, once, Order for future visit					
<input type="checkbox"/> Troponin I Cardiac High Sensitivity Blood, once, Order for future visit					
<input type="checkbox"/> Beta 2 Microglobulin Blood, once, Order for future visit					
<input type="checkbox"/> Hepatitis B Viral Load (Rx monitoring) (HBV ... Blood, once, Order for future visit					

Versioning: Yes

Jira: CST- 359314

Protocols: LYCHOPR, LYDHAPR

Cycles/PowerPlans: All associated treatment plans

Changes:

ONCP LYCHOPR Pretreatment Plan

- **Added** preselected Creatinine and Estimated GFR
- **Added** yellow CDS note 'If clinically indicated:
- **Added** unselected Alkaline Phosphatase, Electrolyte Panel Outpatient (Na, K), Magnesium Level, Calcium Level

ONCP LY LYCHOPR Pretreatment Plan, Baseline Labs (Day 1) (Future Pending) *Est. 14-Mar-2026 08:00 PDT - 1 Days		
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> CBC and Differential	Blood, once, Order for future visit
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine and Estimated GFR	Blood, once, Order for future visit
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Bilirubin Total	Blood, once, Order for future visit
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Alanine Aminotransferase	Blood, once, Order for future visit
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Hepatitis B Core Antibody Total BCCDC	Blood, once, Order for future visit
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Hepatitis B Surface Antigen BCCDC	Blood, once, Order for future visit
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Hepatitis B Surface Antibody BCCDC	Blood, once, Order for future visit
	If HBsAg or HBcoreAb positive, follow hepatitis B prophylaxis as per SCHBV protocol	
	If clinically indicated:	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Alkaline Phosphatase	Blood, once, Order for future visit
<input type="checkbox"/>	<input checked="" type="checkbox"/> Sodium and Potassium Panel (Electrolytes ...	Blood, once, Order for future visit
<input type="checkbox"/>	<input checked="" type="checkbox"/> Magnesium Level	Blood, once, Order for future visit
<input type="checkbox"/>	<input checked="" type="checkbox"/> Calcium Level	Blood, once, Order for future visit

ONCP LYCHOPR Cyclophosphamide Hyperbilirubinemia Option/ONCP LY LYCHOPR DOXOrubicin Option/ONCP LY LYCHOPR Etoposide Cardiac Dysfunction Option

- **Added** additional yellow note: Link to Protocol: Treatment of Mantle Cell Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRISTine, predniSONE and riTUXimab (LYCHOPR) Alternating with Dexamethasone, Cytarabine, Platinum and riTUXimab (LYDHAPR)
- **Re-sequenced and** preselected Creatinine and Estimated GFR, Alanine Aminotransferase and Bilirubin Total
- **Added** unselected Alkaline Phosphatase, Electrolyte Panel Outpatient (Na, K), Magnesium Level, Calcium Level

ONCP LY LYCHOPR Cyclophosphamide Hyperbilirubinemia Option - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est. 19-Mar-2026 08:00 PDT - 21 Days		
	Link to Protocol: Treatment of Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRISTine, predniSONE and riTUXimab (CHOP-R)	
	Link to Protocol: Treatment of Mantle Cell Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRISTine, predniSONE and riTUXimab (LYCHOPR) Alternating with Dexamethasone, Cytarabine, Platinum and riTUXimab (LYDHAPR)	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine and Estimated GFR	Blood, once, Order for future visit
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Alanine Aminotransferase	Blood, once, Order for future visit
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Bilirubin Total	Blood, once, Order for future visit
	If clinically indicated:	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Alkaline Phosphatase	Blood, once, Order for future visit
<input type="checkbox"/>	<input checked="" type="checkbox"/> Sodium and Potassium Panel (Electrolytes ...	Blood, once, Order for future visit
<input type="checkbox"/>	<input checked="" type="checkbox"/> Calcium Level	Blood, once, Order for future visit
<input type="checkbox"/>	<input checked="" type="checkbox"/> Magnesium Level	Blood, once, Order for future visit
<input type="checkbox"/>	<input checked="" type="checkbox"/> Lactate Dehydrogenase	Blood, once, Order for future visit

ONCP LY LYDHAPR CARBOplatin Option/ ONCP LY LYDHAPR CISplatin Option/ ONCP LY LYDHAPR CISplatin Split Dosing Option

- **Added** additional yellow note: Link to Protocol: Treatment of Mantle Cell Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRISTine, predniSONE and riTUXimab (LYCHOPR) Alternating with Dexamethasone, Cytarabine, Platinum and riTUXimab (LYDHAPR)
- **Prechemo metrics updated** from 72h to 96h in ONCP LY LYDHAPR CARBOplatin Option/ONCP LY LYDHAPR CISplatin Option and Lab phase offset by 17d.
- **Prechemo metrics updated** in ONCP LY LYDHAPR Split CISplatin Option. Updated from 48h to 96h and another bundle of metrics created for Day 8 for 48 h. Lab offsets updated to 3 day
- Updated teal note to read 'Patient to start dexamethasone 0.1% eye drops immediately before the first dose of cytarabine and patient to continue every 6 hours until 48 hours after the last dose of cytarabine in each cycle'
- **Added** unselected Lactate Dehydrogenase

4 ONCP LY LYDHAPR CARBOplatin Option - Cycle 1, Chemotherapy (Day 1 to 3) (Future Pending) *Est. 19-Mar-2026 08:00 PDT - 21 Days
 Link to Protocol: Treatment of Lymphoma with Dexamethasone, Cytarabine, Platinum and riTUXimab
 Link to Protocol: Treatment of Mantle Cell Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRISTine, predniSONE and riTUXimab (LYCHOPR) Alternating with Dexamethasone, Cytarabine, Platinum and riTUXimab (LYDHAPR)

Pre-Chemo Metrics
May proceed with treatment on Day 1 if:
Neutrophils Greater Than or Equal to $1.0 \times 10^9/L$ within 96 hours
Platelet Count Greater Than or Equal to $75 \times 10^9/L$ within 96 hours
Creatinine Clearance Greater Than or Equal to 60 mL/min within 96 hours

Patient to start dexamethasone 0.1% eye drops immediately before the first dose of cytarabine and patient to continue every 6 hours until 48 hours after the last dose of cytarabine in each cycle

4 ONCP LY LYDHAPR CARBOplatin Option - Cycle 1, Next Cycle Labs (Day 1) (Future Pending) *Est. 01-Apr-2026 08:00 PDT - 21 Days		
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> CBC and Differential	Blood, once, Order for future visit
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Creatinine and Estimated GFR	Blood, once, Order for future visit
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Alanine Aminotransferase	Blood, once, Order for future visit
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Bilirubin Total	Blood, once, Order for future visit
	If clinically indicated:	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Alkaline Phosphatase	Blood, once, Order for future visit
<input type="checkbox"/>	<input checked="" type="checkbox"/> Sodium and Potassium Panel (Electrolytes ...	Blood, once, Order for future visit
<input type="checkbox"/>	<input checked="" type="checkbox"/> Calcium Level	Blood, once, Order for future visit
<input type="checkbox"/>	<input checked="" type="checkbox"/> Magnesium Level	Blood, once, Order for future visit
<input type="checkbox"/>	<input checked="" type="checkbox"/> Lactate Dehydrogenase	Blood, once, Order for future visit
	If clinically indicated, every 3 months:	
<input type="checkbox"/>	<input checked="" type="checkbox"/> Hepatitis B Viral Load (Rx monitoring) (HB...	Blood, once, Order for future visit

Versioning: Yes

Jira: CST-356784

Protocols: GUTEM

Cycles/PowerPlans: All associated PowerPlans and regimens

Changes:

GUTEM will be retired on 1 April 2026

Versioning: No

Jira: CST-358946

Protocols: LYCDA

Cycles/PowerPlans: Associated treatment PowerPlans

Changes:

In the Chemotherapy phase, added a yellow note:

- Ensure antiviral VZV prophylaxis is in place

ONCP LY LYCDA 3 Day Option - Cycle 1, Chemotherapy (Day 1 to 3) (Future Pe

Component
Link to Protocol: Treatment of Hairy Cell Leukemia with Cladribine
Revised: 2 Dec 2024
This plan is for patients with Creatinine Clearance between 30 and Less Than 70 mL/min. If Creatinine Clearance is Greater Than or Equal to 70 mL/min, please use 5 day option
Cladribine is usually given only once. There is no dose reduction for hematologic blood counts for this first cycle. If repeated, it should be given after recovery of blood counts to baseline following the dose reductions per protocol
First cycle: Proceed with full dose as ordered, regardless of blood counts. Adjust dose for Creatinine Clearance only, if required
Treatment Regimen
Ensure antiviral VZV prophylaxis is in place
Zero Time

Versioning: Yes

Jira: CST-359641

Protocols: MYDBLDF

Cycles/PowerPlans: Associated treatment PowerPlans

Changes:

In the Chemotherapy phase, update yellow note to:

- Ensure antiviral VZV prophylaxis is in place

ONCP MY MYBLDF Female of Childbearing Potential (FCBP) Cycle 1 - Cycle 1,	
Component	*Est
<ul style="list-style-type: none"> Link to Protocol: Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Bortezomib, Lenalidomide and Dexam... Revised: 2 Dec 2024 Pre-Chemo Metrics May proceed with treatment on Day 1 if: <ul style="list-style-type: none"> Neutrophils Greater Than or Equal to $1.0 \times 10^9/L$ within 96 hours Platelet Count Greater Than or Equal to $50 \times 10^9/L$ within 96 hours eGFR or creatinine clearance as per protocol within 96 hours Negative pregnancy test result required prior to treatment. Refer to protocol for specific timeline requirements for testing Treatment Regimen <ul style="list-style-type: none"> Ensure antiviral VZV prophylaxis in in place 	

Versioning: Yes

Jira: CST-360795

Protocols: UGIAPPEM and UGIAPPEM6

Cycles/PowerPlans: ONCP GI UGIAPPEM, ONCP GI UGIAPPEM Pretreatment Plan, ONCP GI UGIAPPEM6 and ONCP GI UGIAPPEM6 Pretreatment Plan

Regimens: ONC GI GIAVPEM and ONC GI GIAVPEM6

Changes:

REGIMENS:

- **Update** name ONC GI UGIAPPEM Regimen to **ONC GI GIAVPEM**
- **Update** name ONC GI UGIAPPEM6 Regimen to **ONC GI GIAVPEM6**
- **Remove** Note Text: 'A BC Cancer "Compassionate Access Program" (CAP) request form must be completed and approved prior to treatment' from both regimens'
- **Remove** 'A BC Cancer "Compassionate Access Program" (CAP) request form must be completed and approved prior to treatment' from both regimens' from Regimen description

ONC GI GIAVPEM (Pending)

▼ Hide additional details

Regimen description: First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using Pembrolizumab

ONC GI GIAVPEM6 (Pending)

▼ Hide additional details

Regimen description: First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using 6-Weekly Pembrolizumab

ONCP GI UGIAPPEM

- **Update** title to **ONCP GI GIAVPPEM**
- Chemotherapy Phase
 - **Update** yellow CDS note - Revised: 1 Apr 2026
- Scheduling Phase
 - **Update** “Infusion Chemotherapy Visit” order - Reason for exam: ONCP GI GIAVPPEM

<input checked="" type="checkbox"/> ONCP GI GIAVPPEM - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est. 26-Mar-2026 08:00 PDT - 21 Days Link to Protocol: First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using Pembrolizumab Revised: 1 Apr 2026	
<input checked="" type="checkbox"/> ONCP GI GIAVPPEM - Cycle 1, Scheduling (Initiated Pending) 26-Mar-2026 08:00 PDT <input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, Cycle 1: Chair time 105 minutes; Nurse time 60 minutes, Chair Time: 75 minutes, Nurse Time: 45 minutes Day 1

ONCP GI UGIAVPPEM Pretreatment

- **Update** title to **ONCP GI GIAVPPEM Pretreatment Plan**
- Baseline Labs
 - **Remove** yellow CDS note

Component	Status	Dose ...	Details
<input checked="" type="checkbox"/> ONCP GI UGIAVPPEM Pretreatment Plan, Baseline Labs (Day 1) (Future Pending) *Est. 26-Mar-2026 08:00 PDT - 1 Days			
<input checked="" type="checkbox"/> CBC and Differential			Blood, once, Order for future visit
<input checked="" type="checkbox"/> Creatinine and Estimated GFR			Blood, once, Order for future visit

ONCP GI UGIAVPPEM6

- **Update** title to **ONCP GI GIAVPPEM6**
- Chemotherapy Phase
 - **Update** yellow CDS note - Revised: 1 Apr 2026
- Scheduling Phase
 - **Update** “Infusion Chemotherapy Visit” order - Reason for exam: ONCP GI GIAVPPEM6

<input checked="" type="checkbox"/> ONCP GI GIAVPPEM6 - Cycle 1, Chemotherapy (Day 1) (Future Pending) *Est. 26-Mar-2026 08:00 PDT - 42 Days Link to Protocol: First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using 6-Weekly Pembrolizumab Revised: 1 Apr 2026	
<input checked="" type="checkbox"/> ONCP GI GIAVPPEM6 - Cycle 1, Scheduling (Initiated Pending) 26-Mar-2026 08:00 PDT <input checked="" type="checkbox"/> Infusion Chemotherapy Visit	Within 2 Weeks, Cycle 1: Chair time 105 minutes; Nurse time 60 minutes, Chair Time: 75 minutes, Nurse Time: 45 minutes Day 1

ONCP GI UGIAVPPEM6 Pretreatment

- **Update** title to **ONCP GI GIAVPPEM6 Pretreatment Plan**
- Baseline Labs
 - **Remove** yellow CDS note

Component	Status	Dose ...	Details
<input checked="" type="checkbox"/> ONCP GI GIAVPPEM6 Pretreatment Plan, Baseline Labs (Day 1) (Future Pending) *Est. 26-Mar-2026 08:00 PDT - 1 Days			
<input checked="" type="checkbox"/> CBC and Differential			Blood, once, Order for future visit
<input checked="" type="checkbox"/> Creatinine and Estimated GFR			Blood, once, Order for future visit

Versioning: Y

Jira: CST-360910

Protocols: ULYOGLOFIT

Cycles/PowerPlans: ULYOGLOFIT Cycle 2 Inpatient and ONCP LY ULYOGLOFIT (Inpatient) Cycle 1 Day 15

Changes:

- Removed **sodium chloride 0.9% (NS) continuous infusion** order linked to glofitamab - oncology order
- Updated **glofitamab – oncology** order administer over from 8 hour to 4 hour. **30 mg, IV, once oncology, administer over: 4 hour, drug form: bag**

- Updated **glofitamab – oncology** order Comment: **Day 2 or Day 15**. Removed first sentence: **Y-site compatible with sodium chloride 0.9% continuous infusion**
- Updated revised Date: Revised: **1 Apr 2026**

ONCP LY ULYOGLOFIT (Inpatient) Cycle 2 - Cycle 2, Chemotherapy (Day 1) (Future Pending) *Est. 25-Mar-2026 12:19 PDT - 21 Days

Component	Day 1	Future Pending	*Est. 25-Mar-2026
<ul style="list-style-type: none"> Patients should be counselled on the signs and symptoms of CRS and ICANS and to seek immediate medical attention should they occur Vital signs prior to glofitamab, every hour during infusion, at the end of the infusion, and as clinically indicated 			
<ul style="list-style-type: none"> glofitamab (glofitamab - oncology) 30 mg, IV, once oncology, administer over: 4 ho... Day 1 	Planned	0 min	
<ul style="list-style-type: none"> Responsible provider must assess patient and review labs (if ordered) drawn day after treatment prior to discharge Additional Orders Any additional orders will be displayed below. Please review and adjust scheduled administration time as needed 			
			glofitamab (glofitamab - oncology) Component: 30 mg, IV, once oncology, administer over: 4 hour, drug form: bag Order Comment: Day 1

Order Comment Updated

Versioning: Yes

Jira: CST-358786

Net New Protocols

ONC GI GIAVIPNI
 ONCP GI GIAVIPNI Induction
 ONCP GI GIAVIPNI Maintenance
 ONCP GI GIAVIPNI Pretreatment Plan

ONC LU ULUAVPPAF Weight Less than 80 kg
 ONC LU ULUAVPPAF Weight 80 kg or more
 ONCP LU ULUAVPPAF Baseline Weight 80 kg or more Cycle 1
 ONCP LU ULUAVPPAF Baseline Weight 80 kg or more Cycle 2
 ONCP LU ULUAVPPAF Baseline Weight 80 kg or more Cycles 3 and 4
 ONCP LU ULUAVPPAF Baseline Weight 80 kg or more Cycles 5+
 ONCP LU ULUAVPPAF Baseline Weight Less than 80 kg Cycle 1
 ONCP LU ULUAVPPAF Baseline Weight Less than 80 kg Cycle 2
 ONCP LU ULUAVPPAF Baseline Weight Less than 80 kg Cycles 3 and 4
 ONCP LU ULUAVPPAF Baseline Weight Less than 80 kg Cycles 5+
 ONCP LU ULUAVPPAF Pretreatment Plan

ONC LU ULUAVPPAMI Baseline Weight Less than 80 kg
 ONC LU ULUAVPPAMI Baseline Weight 80 kg or more
 ONCP LU ULUAVPPAMI Baseline Weight Less than 80 kg Cycle 1
 ONCP LU ULUAVPPAMI Baseline Weight Less than 80 kg Cycle 2
 ONCP LU ULUAVPPAMI Baseline Weight Less than 80 kg Cycles 3 and 4
 ONCP LU ULUAVPPAMI Baseline Weight Less than 80 kg Cycle 5+
 ONCP LU ULUAVPPAMI Baseline Weight 80 kg or more Cycle 1
 ONCP LU ULUAVPPAMI Baseline Weight 80 kg or more Cycle 2

ONCP LU ULUAVPPAMI Baseline Weight 80 kg or more Cycles 3 and 4
ONCP LU ULUAVPPAMI Baseline Weight 80 kg or more Cycle 5+

ONC GI GIIPNI

ONCP GI GIIPNI Pretreatment Plan

ONCP GI GIIPNI Induction

ONCP GI GIIPNI Every 4 Week Maintenance

ONC LY LYMCALT LYCHOPR Cyclophosphamide Hyperbilirubinemia and LYDHAPR CARBOplatin Option

ONC LY LYMCALT LYCHOPR Cyclophosphamide Hyperbilirubinemia and LYDHAPR CISplatin Option

ONC LY LYMCALT LYCHOPR Cyclophosphamide Hyperbilirubinemia and LYDHAPR Split CISplatin Option

ONC LY LYMCALT LYCHOPR DOXOrubicin and LYDHAPR CARBOplatin Option

ONC LY LYMCALT LYCHOPR DOXOrubicin and LYDHAPR CISplatin Option

ONC LY LYMCALT LYCHOPR DOXOrubicin and LYDHAPR Split CISplatin Option

ONC LY LYMCALT LYCHOPR Etoposide Cardiac Dysfunction and LYDHAPR CARBOplatin Option

ONC LY LYMCALT LYCHOPR Etoposide Cardiac Dysfunction and LYDHAPR CISplatin Option

ONC LY LYMCALT LYCHOPR Etoposide Cardiac Dysfunction and LYDHAPR Split CISplatin Option

ONC LY LYCLADR 3 Day Option

ONC LY LYCLADR 5 Day Option

ONCP LY LYCLADR Pretreatment Plan

ONCP LY LYCLADR 3 Day Option Week 1

ONCP LY LYCLADR 5 Day Option Week 1

ONCP LY LYCLADR Week 2 to 8

ONC HN HNAJALPCRT Every 3 Week Option

ONC HN HNAJALPCRT Every 6 Week Option

ONCP HN HNAJALPCRT Cycle 3

ONCP HN HNAJALPCRT Cycles 1 to 2

ONCP HN HNAJALPCRT Every 3 Week Option Cycles 4+

ONCP HN HNAJALPCRT Every 6 Week Option Cycles 4+

ONCP HN HNAJALPCRT Pretreatment Plan

ONC HN HNAJPMBCRT Every 3 Week Option

ONC HN HNAJPMBCRT Every 6 Week Option

ONCP HN HNAJPMBCRT Cycle 3

ONCP HN HNAJPMBCRT Cycles 1 to 2

ONCP HN HNAJPMBCRT Every 3 Week Option Cycles 4+

ONCP HN HNAJPMBCRT Every 6 Week Option Cycles 4+

ONCP HN HNAJPMBCRT Pretreatment Plan

ONC HN HNAJALPPRT Every 3 Week Option

ONC HN HNAJALPPRT Every 6 Week Option

ONCP HN HNAJALPPRT Pretreatment Plan

ONCP HN HNAJALPPRT Cycles 1 to 2

ONCP HN HNAJALPPRT Cycle 3

ONCP HN HNAJALPPRT Every 3 Week Cycles 4+

ONCP HN HNAJALPPRT Every 6 Week Cycles 4+

ONC HN HNAJPMBPRT Long Hydration (Inpatient) and Pembrolizumab and CISplatin Option Cycle 3
 ONC HN HNAJPMBPRT Long Hydration (Inpatient) and Pembrolizumab Only Option Cycle 3
 ONC HN HNAJPMBPRT Short Hydration and Pembrolizumab and CISplatin Option Cycle 3
 ONC HN HNAJPMBPRT Short Hydration and Pembrolizumab Only Option Cycle 3
 ONC HN HNAJPMBPRT Every 3 Week Option Cycle 4+
 ONC HN HNAJPMBPRT Every 6 Week Option Cycle 4+
 ONCP HN HNAJPMBPRT Every 3 Week Option Cycles 4+
 ONCP HN HNAJPMBPRT Every 6 Week Option Cycles 4+
 ONCP HN HNAJPMBPRT Long Hydration Option (Inpatient) Cycles 1 and 2
 ONCP HN HNAJPMBPRT Pembrolizumab Only Option Cycle 3
 ONCP HN HNAJPMBPRT Pembrolizumab and CISplatin Long Hydration Option (Inpatient) Cycle 3
 ONCP HN HNAJPMBPRT Pembrolizumab and CISplatin Short Hydration Option Cycle 3
 ONCP HN HNAJPMBPRT Pretreatment Plan
 ONCP HN HNAJPMBPRT Short Hydration Option Cycles 1 and 2

ONC HN HNAJPMB Every 3 Week Option
 ONC HN HNAJPMB Every 6 Week Option
 ONCP HN HNAJPMB Pretreatment Plan
 ONCP HN HNAJPMB Cycles 1 to 3
 ONCP HN HNAJPMB Every 3 Week Option Cycles 4+
 ONCP HN HNAJPMB Every 6 Week Option Cycles 4+

ONC HN HNNAPMB
 ONCP HN HNNAPMB
 ONCP HN HNNAPMB Pretreatment Plan

Jira: CST-358603, CST-358602, CST-358154, CST-358153, CST-355470, CST-354622, CST-354565, CST-354564, CST-354562, CST-354561, CST-354559, CST-354558, CST-360910

Jira Ticket #	CST-360910, 360795, CST-359641, CST- 359314, CST-358946, CST-358786, CST-356784 CST-358603, CST-358602, CST-358154, CST-358153, CST-355470, CST-354622, CST-354565, CST-354564, CST-354562, CST-354561, CST-354559, CST-354558, CST-360910
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Cerner Phone Support: 1-844-214-7444